Loading...
•
Sep 30, 2020
Marinus Pharmaceuticals Q3 2020 Earnings Report
Reported financial results for the third quarter ended September 30, 2020.
Key Takeaways
Marinus Pharmaceuticals reported positive results from the Marigold Study and progress in its status epilepticus program. The company had cash, cash equivalents and investments of $91.3 million as of September 30, 2020, which is expected to fund operations into 2022.
Positive results from Marigold Study demonstrated ganaxolone’s potential as a treatment for CDD patients.
Significant progress achieved in status epilepticus program, including a cost-sharing contract with BARDA.
Strengthened the organization with new hires to support clinical trials, commercial planning, and portfolio development.
Cash, cash equivalents and investments of $91.3 million as of September 30, 2020.